Naloxone enhances the increase in plasma growth hormone induced by α2-adrenergic stimulation in healthy males

Publisher Website
Google Scholar
Abstract
There is evidence that the .alpha.2-adrenergic agonist clonidine interacts with the opioid system. In the present investigations, the effect of naloxone on the increase in plasma GH induced by clonidine and the more specific .alpha.2-agonist guanfacine was studied in man. In a single-blind study, five healthy males received in randomized order either the preservatives in the naloxone preparation (control) or naloxone at two different doses (10 or 100 .mu.g/kg) followed by an infusion of either diluted preservatives or naloxone (5 or 50 .mu.g .cntdot. kg-1 .cntdot. h-1, respectively). Fifteen min after the bolus dose, clonidine (3 .mu.g/kg) or guanfacine (15 .mu.g/kg) was infused over 10 min in a single-blind order. Both clonidine and guanfacine induced an increase in plasma GH (P < 0.05). Pre-treatment with naloxone at the higher dosage resulted in an enhanced (P < 0.05) GH response to clonidine and guanfacine, respectively, whereas the lower dosage of naloxone was without effect. The increase in plasma GH did not correlate with basal mean arterial blood pressure, nor with the changes in mean arterial blood pressure induced by clonidine or guanfacine. These results indicate that the increase in plasma GH induced by .alpha.2-adrenergic stimulation in normotensive subjects involves opioid receptors with moderate sensitivity to naloxone.